A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†Giuseppe Cabibbo, Calogero Cammà|Hepatology|2009Cited by 479
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patientsGiuseppe Cabibbo, Calogero Cammà, Gaetano Scifo et al.|Journal of Hepatology|2019Cited by 205
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Giuseppe Cabibbo et al.|The Lancet Oncology|2023Cited by 184
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVíctor Sapena, María Reig, Marco Enea et al.|Gut|2021Cited by 96
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62